Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, was featured in a recent article that discussed its innovative AVERSA(TM) abuse-deterrent technology and business model. “AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao,” the article reads.
A new study focusing on twins has found that individuals with a larger presence of certain bacteria types could have a higher likelihood of developing multiple sclerosis . These findings could offer new ways to halt the disease’s progression or prevent it altogether.
Las Vegas, Nevada - April 24, 2025 - Mods4cars is now launching its retrofit SmartTOP convertible top control system for the 7th Gen Ford Mustang convertible. “We are delighted that we can now also offer a smart convertible top solution for the 7th Gen Ford Mustang Convertible,” says PR spokesman Sven Tornow. The SmartTOP modules are retrofitted to the vehicle to make the convertible top more convenient to operate.
Stem cells are the “master cells” within the body because they can grow into any needed type of specialized cell in one’s body. As cancer treatment advances, these cells are proving to be a lifesaver for many people diagnosed with blood cancers like leukemia, myeloma and lymphoma.
Lyft's 8% market share of the global ride-hailing market trails behind Uber's 25% market share, but its acquisition of FreeNow mobility platform adds Europe
Limo SF VIP (888-888-0195) announces an expanded VIP transportation service available in the San Francisco Bay Area, offering exclusive experiences suited to high-end weddings, special events, luxury city tours, wine tours, and airport transfers.
UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast for 2025 after its customers on Medicare Advantage made use of their policies a lot more than the company had anticipated. The first quarter of the year registered a lower financial performance than the company had expected.
Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number of countries granting protection to 46.
Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period ( https://ibn.fm/viChU ). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
A new study whose findings appeared in the journal Heliyon has found that individuals that suffered neglect, abuse and other forms of maltreatment during their childhood had a notably elevated risk of being diagnosed with chronic immune-related disorders later on in their lives. Psoriasis and rheumatoid arthritis were particularly noted in the study subjects and women exhibited a higher likelihood of developing these immune disorders.
Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue.
Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer. The study focuses on patients developing resistance to osimertinib, aiming to identify those who may benefit from early intervention with ENV105. The funding will support research in Dr. Neil Bhowmick’s lab and aligns with Kairos’ strategy to improve long-term outcomes through targeted therapy and precision monitoring.
The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights.
The company said the deal would increase its annualized gross bookings by approximately €1 billion and diversify revenue streams, supporting its multi-year targets.
"Not Your Basic Locksmith" (682-344-1957) has expanded its professional car locksmith services in Arlington, TX, offering fast, affordable, and efficient solutions for automotive lockouts, key programming, and ignition repair.
Milwaukee, WI () April 10, 2025 -- Milwaukee's trusted auto service provider enhances customer experience with a new digital platform for seamless vehicle repairs and maintenance.
